Clinical Trial Update: To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

This document outlines a Phase II/III trial of Anlotinib in advanced non-small cell lung cancer, focusing on predicting efficacy by measuring circulating endoth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: UNKNOWN